Clinical Trial: Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: International Prospective Phase 2 Trial Addressing the Efficacy of First-line Chlamydophila Psittaci-eradicating Therapy With Protracted Administration of Doxycycline Followed by Eradication Monitorin
Brief Summary: Objective of this trial is to establish the efficacy of an upfront targeted therapy consisting of Chlamydophila psittaci (Cp)-eradicating therapy with prolonged administration of doxycycline followed by eradication monitoring and antibiotic re-treatment at infection re-occurrence in patients with newly diagnosed ocular adnexae marginal zone lymphoma The primary endpoint is the 2-year progression-free survival (PFS) of patients with newly diagnosed stage-IE lymphoma treated with the experimental strategy.
Detailed Summary:
Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Current Primary Outcome: progression-free survival (PFS) [ Time Frame: 2-year from start of treatment ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: International Extranodal Lymphoma Study Group (IELSG)
Dates:
Date Received: March 26, 2013
Date Started: March 2013
Date Completion: September 2023
Last Updated: July 26, 2016
Last Verified: July 2016